CSF3 and myeloid neoplasm: Mecapegfilgrastim is a new agent in the family of long-acting granulocyte colony-stimulating factors (G-CSF), and is intended for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer therapy associated with a clinically significant incidence of leucopenia and febrile neutropenia.